Physician profile
Mark J Quinn
NPI 1558324541
$1,090.14
in general payments reported to CMS, 2019-2025
14 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $324 · 2022: $201 · 2023: $150 · 2024: $248 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.50 | 2021-2025 | |
| Glaxosmithkline, LLC. | $136.11 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $122.15 | 2022-2025 | Veozah, Cresemba |
| Biohaven Pharmaceuticals, INC. | $91.30 | 2021 | |
| Pfizer INC. | $59.85 | 2023-2024 | |
| Lilly USA, LLC | $59.64 | 2021-2024 | Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $56.49 | 2022 | |
| Amgen INC. | $35.62 | 2021-2025 | Evenity |
| Eisai INC. | $34.82 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.21 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $20.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.67 | 2023 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $16.68 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.